Duvelisib Maintenance for the Treatment of Peripheral T-Cell Lymphomas
Plain-language summary
This Phase 2 trial is evaluating Biospecimen Collection, Bone Marrow Aspiration, and other medications as a treatment for people newly diagnosed with a type of T-cell lymphoma called AITL. The study measures how well this treatment works and monitors for side effects. It is available at 1 US location.
Who can join (key eligibility)
- Age 18 Years or older
- Newly diagnosed, not yet treated
- Must be well enough for treatment (adequate performance status)
- May require specific number of prior treatments
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
Biospecimen Collection (PROCEDURE): Undergo blood sample collection | Bone Marrow Aspiration (PROCEDURE): Undergo bone marrow aspiration | Bone Marrow Biopsy (PROCEDURE): Undergo bone marrow biopsy | Computed Tomography (PROCEDURE): Undergo CT scan | Duvelisib (DRUG): Given PO | Positron Emission Tomography (PROCEDURE): Undergo PET scan | Survey Administration (OTHER): Ancillary studies
- Drugs / treatments
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Duvelisib, Positron Emission Tomography, Survey Administration
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details